Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
Canada
Toronto, Toronto, Ontario Montréal, Montreal, Quebec Montreal, Montreal, Quebec Sherbrooke, Sherbrooke, Quebec Finland
Tampere, Tampere, Pirkanmaa Turku, Turku, Southwest Finland United Kingdom
London, London, Greater London Glasgow, Glasgow, Scotland